DM has received consultancy from Janssen, AstraZeneca, Chugai, AbbVie, Genmab, Sanofi, BMS, and Pfizer; has received research funding from Ono, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Otsuka, Pfizer, Loxo Oncology, Eli Lilly, and Incyte Japan; has received honoraria from Ono, Nippon Shinyaku, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, and BeiGene. NY has received research funding from Chugai, Roche, Ono, Genmab, and Tanabe-Mitsubishi; has received honoraria from Chugai, Genmab, AbbVie, Takeda, Novartis, Mundi Pharma, Daiichi-Sankyo, Kyowa-Kirin, Johnson & Johnson, and BeiGene.